pH Sensitive Solid Lipid Nanoparticles of Linagliptin using
Quality by Design approach for the treatment of Diabetes Mellitus
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: VENI, D. Krishna (JSS College of Pharmacy, Pharmaceutics, Mysuru, India)
- Co-author(s): D. Krishna Veni: Pharmaceutics, JSS College of Pharmacy, Mysuru, India
N. Vishal Gupta: Pharmaceutics, JSS College of Pharmacy, Mysuru, India
Linagliptin is a DPP-4 Inhibitor used in the treatment of Type II Diabetes. One of the major challenges of this drug was found to be degradation in the gastric environment which lead to low bioavailability. In this study to overcome this challenge drug has been enteric coated with a pH sensitive polymer and formulated as solid lipid.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.